Authors
Jaspreet Toor, Emily R Adams, Maryam Aliee, Benjamin Amoah, Roy M Anderson, Diepreye Ayabina, Robin Bailey, Maria-Gloria Basáñez, David J Blok, Seth Blumberg, Anna Borlase, Rocio Caja Rivera, María Soledad Castaño, Nakul Chitnis, Luc E Coffeng, Ronald E Crump, Aatreyee Das, Christopher N Davis, Emma L Davis, Michael S Deiner, Peter J Diggle, Claudio Fronterre, Federica Giardina, Emanuele Giorgi, Matthew Graham, Jonathan ID Hamley, Ching-I Huang, Klodeta Kura, Thomas M Lietman, Tim CD Lucas, Veronica Malizia, Graham F Medley, Aronrag Meeyai, Edwin Michael, Travis C Porco, Joaquin M Prada, Kat S Rock, Epke A Le Rutte, Morgan E Smith, Simon EF Spencer, Wilma A Stolk, Panayiota Touloupou, Andreia Vasconcelos, Carolin Vegvari, Sake J de Vlas, Martin Walker, T Déirdre Hollingsworth
Publication date
2021/4/15
Source
Clinical Infectious Diseases
Volume
72
Issue
8
Pages
1463-1466
Publisher
Oxford University Press
Description
Due to the COVID-19 pandemic, many key neglected tropical disease (NTD) activities have been postponed. This hindrance comes at a time when the NTDs are progressing towards their ambitious goals for 2030. Mathematical modelling on several NTDs, namely gambiense sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases (STH), trachoma, and visceral leishmaniasis, shows that the impact of this disruption will vary across the diseases. Programs face a risk of resurgence, which will be fastest in high-transmission areas. Furthermore, of the mass drug administration diseases, schistosomiasis, STH, and trachoma are likely to encounter faster resurgence. The case-finding diseases (gambiense sleeping sickness and visceral leishmaniasis) are likely to have fewer cases being detected but may face an increasing underlying rate of new infections. However …
Scholar articles
J Toor, ER Adams, M Aliee, B Amoah, RM Anderson… - Clinical Infectious Diseases, 2021